S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Introducing MarketBeat All Access (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Biden and GOP reach debt-ceiling deal. Now Congress must approve it to prevent calamitous default
Introducing MarketBeat All Access (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Erdogan takes lead in unofficial count in Turkey’s presidential runoff
Introducing MarketBeat All Access (Ad)
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Introducing MarketBeat All Access (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Biden and GOP reach debt-ceiling deal. Now Congress must approve it to prevent calamitous default
Introducing MarketBeat All Access (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Erdogan takes lead in unofficial count in Turkey’s presidential runoff
Introducing MarketBeat All Access (Ad)
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Introducing MarketBeat All Access (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Biden and GOP reach debt-ceiling deal. Now Congress must approve it to prevent calamitous default
Introducing MarketBeat All Access (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Erdogan takes lead in unofficial count in Turkey’s presidential runoff
Introducing MarketBeat All Access (Ad)
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Introducing MarketBeat All Access (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Biden and GOP reach debt-ceiling deal. Now Congress must approve it to prevent calamitous default
Introducing MarketBeat All Access (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Erdogan takes lead in unofficial count in Turkey’s presidential runoff
Introducing MarketBeat All Access (Ad)
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
NASDAQ:ALPN

Alpine Immune Sciences (ALPN) Stock Forecast, Price & News

$9.90
-0.15 (-1.49%)
(As of 05/26/2023 ET)
Compare
Today's Range
$9.84
$10.21
50-Day Range
$6.84
$10.54
52-Week Range
$4.82
$10.95
Volume
76,574 shs
Average Volume
180,027 shs
Market Capitalization
$474.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.40

Alpine Immune Sciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
65.7% Upside
$16.40 Price Target
Short Interest
Bearish
2.40% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.45mentions of Alpine Immune Sciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.43) to ($1.73) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.61 out of 5 stars

Medical Sector

869th out of 1,012 stocks

Pharmaceutical Preparations Industry

435th out of 495 stocks


ALPN stock logo

About Alpine Immune Sciences (NASDAQ:ALPN) Stock

Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies. The company was founded in March 2007 and is headquartered in Seattle, WA.

Receive ALPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alpine Immune Sciences and its competitors with MarketBeat's FREE daily newsletter.

ALPN Stock News Headlines

"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
Q4 2022 Alpine Immune Sciences Inc Earnings Call
See More Headlines
Receive ALPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alpine Immune Sciences and its competitors with MarketBeat's FREE daily newsletter.

ALPN Company Calendar

Last Earnings
3/23/2023
Today
5/28/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALPN
Employees
85
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.40
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+65.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-57,760,000.00
Net Margins
-245.92%
Pretax Margin
-236.91%

Debt

Sales & Book Value

Annual Sales
$25.82 million
Book Value
$3.53 per share

Miscellaneous

Free Float
21,729,000
Market Cap
$474.86 million
Optionable
Not Optionable
Beta
1.26

Key Executives

  • Mitchell H. GoldMitchell H. Gold
    Executive Chairman & Chief Executive Officer
  • Stanford L. Peng
    President & Head-Research & Development
  • Thaedra Thullberry
    Finance Director
  • James Paul Rickey
    Chief Financial Officer, Secretary & Senior VP
  • Wayne R. Gombotz
    Chief Technology Officer













ALPN Stock - Frequently Asked Questions

Should I buy or sell Alpine Immune Sciences stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALPN shares.
View ALPN analyst ratings
or view top-rated stocks.

What is Alpine Immune Sciences' stock price forecast for 2023?

4 Wall Street research analysts have issued twelve-month target prices for Alpine Immune Sciences' shares. Their ALPN share price forecasts range from $11.00 to $25.00. On average, they predict the company's share price to reach $16.40 in the next twelve months. This suggests a possible upside of 65.7% from the stock's current price.
View analysts price targets for ALPN
or view top-rated stocks among Wall Street analysts.

How have ALPN shares performed in 2023?

Alpine Immune Sciences' stock was trading at $7.35 at the beginning of 2023. Since then, ALPN stock has increased by 34.7% and is now trading at $9.90.
View the best growth stocks for 2023 here
.

Are investors shorting Alpine Immune Sciences?

Alpine Immune Sciences saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 1,150,000 shares, an increase of 8.5% from the April 30th total of 1,060,000 shares. Based on an average daily trading volume, of 107,200 shares, the days-to-cover ratio is presently 10.7 days.
View Alpine Immune Sciences' Short Interest
.

When is Alpine Immune Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ALPN earnings forecast
.

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) posted its quarterly earnings data on Thursday, March, 23rd. The biotechnology company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by $0.14. The biotechnology company had revenue of $2.78 million for the quarter, compared to analysts' expectations of $10.42 million. Alpine Immune Sciences had a negative net margin of 245.92% and a negative trailing twelve-month return on equity of 40.29%.

What other stocks do shareholders of Alpine Immune Sciences own?
What is Alpine Immune Sciences' stock symbol?

Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."

Who are Alpine Immune Sciences' major shareholders?

Alpine Immune Sciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Great Point Partners LLC (7.80%), BlackRock Inc. (3.24%), BVF Inc. IL (1.79%), Geode Capital Management LLC (1.16%), State Street Corp (0.72%) and Renaissance Technologies LLC (0.69%). Insiders that own company stock include Decheng Capital China Life Sci, Life Sciences Viii L Frazier, Mitchell Gold, Orbimed Advisors Llc, Robert E Conway and Robert E Conway.
View institutional ownership trends
.

How do I buy shares of Alpine Immune Sciences?

Shares of ALPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alpine Immune Sciences' stock price today?

One share of ALPN stock can currently be purchased for approximately $9.90.

How much money does Alpine Immune Sciences make?

Alpine Immune Sciences (NASDAQ:ALPN) has a market capitalization of $474.86 million and generates $25.82 million in revenue each year. The biotechnology company earns $-57,760,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

How can I contact Alpine Immune Sciences?

Alpine Immune Sciences' mailing address is 188 East Blaine Street Suite 200, Seattle WA, 98102. The official website for the company is www.alpineimmunesciences.com. The biotechnology company can be reached via phone at (206) 788-4545, via email at laurence@gilmartinir.com, or via fax at 303-440-8399.

This page (NASDAQ:ALPN) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -